BI: pig vaccine drives strong growth

Boehringer Ingelheim's pig vaccine Ingelvac CircoFlex has helped the pharmaceutical company increase its animal health sales in the first six months of 2009.

The company's animal health business achieved strong growth of +27.9% in local currency (+32.5% in euro), with sales of €286 million. Sales of the vaccine against Porcine Circovirus 2 (PCV2) contributed strongly to that result.

In total, the pharmaceutical company's growth came down to in local currency (+8.3%) over the previous year in the first six months of 2009. Consolidated in euro, this reflected growth of +15.7% thanks to positive exchange rates, with net sales of €6,388 million compared with €5,522 million in the first six months of the previous year.

Prof Dr Dr Andreas Barner, chairman of the board of managing directors: "We have posted growth in our business areas human pharmaceuticals, thanks in particular to the success of our innovative prescription medicines, and in animal health, thanks to the growth in the segment of vaccines.

"Despite the negative impact in some areas as a result of the financial crisis, local business development in the first half of 2009 shows that Boehringer Ingelheim is maintaining its growth course, virtually unchanged, and continues to outpace the pharmaceutical market," Barner said.

Related websites:
Boehringer Ingelheim 

Or register to be able to comment.